Item 8.01    Other Events.
On January 12, 2022, Ocugen, Inc. issued a press release announcing the results
from a study conducted at Emory University demonstrating that sera from subjects
who received a booster dose of the candidate vaccine COVAXIN™ (BBV152) six
months after getting a primary two-dose series of COVAXIN™ neutralized the
SARS-CoV-2 Omicron and Delta variants. A copy of this press release is filed
herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated
herein by reference.
Item 9.01    Financial Statements and Exhibits.
The following exhibits are being filed herewith:
(d) Exhibits
Exhibit No.                Document
99.1                         Press Release of Ocugen, Inc. dated January 12, 2022.
                           Cover Page Interactive Data File (embedded within the Inline XBRL
104                        document).


                                       1

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses